Currently, clinicians face a wide gamut of challenges in the treatment of infectious conditions of the skin. Economic factors generated by healthcare management agencies and beyond the control of the clinician may serve to restrict access to specific medications and indirectly restrict patient access to appropriate care. An area of very recent concern is centered on the growing prevalence of methicillin-resistant Staphylococcus aureus. Herpes simplex virus type 2 prevalence has for the first time shown a surprising downward trend, offsetting the expected continuation in upward escalation seen for the previous decades. Newer pharmacological agents have facilitated control of fungal and parasitic infections. More dermatologists are becoming involved in the field of wound care, where appreciation of microbial colonization may play an equally important role to that of frank wound infection. The novel use of biologicals for the treatment of psoriasis heralds the need for constant vigilance for the potential emergence of granulomatous infections, such as TB.